Eben Fox Email Address

Director External Scientific Affairs, Search and Evaluation, Global Business Development

Daiichi Sankyo, Inc. headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Daiichi Sankyo, Co., Ltd. and a member of the Daiichi Sankyo Group. Global clinical development and regulatory activities are headquartered at Daiichi Sankyo Pharma Development in Edison, New Jersey. \r\n\r\nOur team of more than 1,400 U.S. employees is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs. We currently market therapies in hypertension, thrombotic disorders, stroke risk reduction, dyslipidemia, diabetes, acute coronary syndrome, opioid-induced constipation and metastatic melanoma. \r\n\r\nWith over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group’s 2025 Vision to become a “Global Pharma Innovator with a Competitive Advantage in Oncology,” Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases.\r\n\r\nIMPORTANT NOTE: We are very pleased to announce the location of Daiichi Sankyo, Inc.’s new US headquarters where our Parsippany- and Edison-based teams will be co-located in a combined site in early to mid-2017. Our new headquarters will be in Basking Ridge, New Jersey at 211 Mt. Airy Road.

Experience in multiple alliances with NVS and KAI Pharma as commercial lead and LLY as lifecycle leadSolid track record for integrating scientific and business issues and implementing strategic plans for transitioning new pharmaceutical product candidates to brand marketing for commercial growth.-Major strength in directing pre-market development of product candidates in pipeline through effective cross-functional and cross-cultural relationships with: key opinion leaders, clinical researchers, medical and legal affairs, HEOR, MR and VPA teams, public relations/ad/Med Com agencies, and MR vendors.-Demonstrated ability to generate and implement original ideas that contribute materially to the success and development of drug candidates -Successful in navigating through difficulties, seeking out expert advice, following up on implementation efforts, and delivering well-informed recommendations. -Experience in various therapeutic areas, including: cardiovascular, oncology, bone and joint disease, anti-infectives, gastrointestinal, renal, autoimmune disorders and rare disease (PXE).Specialties: -Using real world data (Marketscan) to answer key business questions-Market research planning-Target product profile creation-Licensing/Market Assessment-Market access and Value proposition planning-Alignment of clinical and commercial needs for Phase III registration-Medical education/publication planning-Draft Launch Label Creation-Competitive analysis-Contingency - Risk management planning